Sociedad Americana de Hirudoterapia

Serum metabolomic profiles reveal the impact of BuZangTongLuo formula on metabolic pathways in diabetic mice with hindlimb ischemia

Research article published in Journal of ethnopharmacology (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaEnsayos clínicosZheng J et al. · Journal of ethnopharmacology, 2020

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: BuZangTongLuo Formula (BZTLF) was the decoction of eight traditional Chinese medicines including Astragalus membranaceus, Dioscorea opposita, Salvia miltiorrhiza, Scrophularia ningpoensis, Ophiopogon japonicus, Panax ginseng, Fritillariae cirrhosae and Whitmania pigra. This formula has been used as an effective remedy for treatment of diabetic ischemia clinically. AIM OF THE STUDY: In previous study, we have reported the therapeutic effect of BZTLF on diabetic vascular dysfunction. However, it remains obscure about the role of metabolic pathways in BZTLF-initiated improvement on hindlimb ischemia. MATERIALS AND METHODS: Diabetic mice with hindlimb ischemia were orally administrated with BZTLF by gavage. The serum samples were prepared for untargeted metabolomic analysis by ultra-performance liquid chromatography-mass spectrometer. The metabolic network was built by integrating metabolite data with the Gene Expression Omnibus (GEO) dataset (GSE3313). Further, quantitative PCR was used to confirm the key target genes. RESULTS: BZTLF treatment remarkably led to the reversal of changed metabolite levels in serum of diabetic mice with hindlimb ischemia, which mainly derived from bacteria, plant and signaling molecules. Also, BZTLF reshaped the metabolic pathways, especially those responsible for metabolism of lipid, gluthanine and tryptophan. In addition, BZTLF led to the reduction of lysophosphatidic acids (LPAs) and increment of triglycerides (TGs) conjugation with non-saturated fatty acids in serum. BZTLF significantly restored the down-regulation of vascular endothelial growth factor receptor 2 (VEGFR2) and endothelial nitric oxide synthase (eNOS) or the up-regulation of interleukin 4-induced 1 (IL4I1) and cytochrome P450 family 1 subfamily B member 1 (CYP1B1) at mRNA level, which were key regulatory genes located in metabolic pathways of glutamate and tryptophan. CONCLUSIONS: BZTLF improved hindlimb ischemia in diabetic mice by the positive regulation of metabolome changes in serum.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsChromatography, High Pressure LiquidDiabetes Mellitus, ExperimentalDrugs, Chinese HerbalHindlimbIschemiaMaleMass SpectrometryMetabolomeMetabolomicsMiceMice, Inbred C57BL

Resumen

BuZangTongLuo Formula (BZTLF) was the decoction of eight traditional Chinese medicines including Astragalus membranaceus, Dioscorea opposita, Salvia miltiorrhiza, Scrophularia ningpoensis, Ophiopogon japonicus, Panax ginseng, Fritillariae cirrhosae and Whitmania pigra.

Por qué esto importa para la hirudoterapia

This serum metabolomics study investigated how BuZangTongLuo Formula—a decoction of eight traditional Chinese medicines including Whitmania pigra leech—affects metabolic pathways in diabetic mice with hindlimb ischemia, finding that treatment reshaped lipid, glutamine, and tryptophan metabolism and modulated key vascular genes (VEGFR2, eNOS, IL4I1, CYP1B1). The leech is only one of eight ingredients in this multi-component formula, so its individual contribution cannot be isolated from these findings. While this provides indirect evidence for leech-containing formulas in vascular disease—a condition relevant to hirudotherapy—the study does not specifically evaluate leech therapy or the leech secretome, making relevance to ASH's domain limited and indirect.

Citación

Serum metabolomic profiles reveal the impact of BuZangTongLuo formula on metabolic pathways in diabetic mice with hindlimb ischemia

Zheng J et al. · Journal of ethnopharmacology, 2020

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.